Literature DB >> 3657335

Topographic brain mapping of EEG in neuropsychopharmacology--Part I. Methodological aspects.

P Anderer1, B Saletu, K Kinsperger, H Semlitsch.   

Abstract

Topographic brain mapping of the electroencephalogram (EEG) is a promising new method in neuropsychiatry and neuropsychopharmacology. Rapid advances in computer technology allow on-line analysis by means of micro-computers. This paper describes an acquisition and signal analysis system for studying neurophysiological and neuropsychopharmacological aspects of human brain function. It consists of a server micro-computer functioning as an acquisition unit which is connected to a workstation micro-computer for statistical analysis and subsequent documentation of data on a printer and color plotter. According to the recommendations for standardization of data acquisition and signal analysis in pharmaco-electroencephalography, the paper mediates detailed information concerning recording and analysis equipment with special emphasis on the treatment of artifacts. Since up to now there is no normative consensus on the choice of reference conventions and interpolation algorithms, the system is designed for high flexibility to enable empirical comparisons between different methods.

Entities:  

Mesh:

Year:  1987        PMID: 3657335

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  19 in total

1.  Dysfunctional pain modulation in somatoform pain disorder patients.

Authors:  Stefanie Klug; Klug Stefanie; Peter Anderer; Anderer Peter; Gerda Saletu-Zyhlarz; Saletu-Zyhlarz Gerda; Marion Freidl; Freidl Marion; Bernd Saletu; Saletu Bernd; Wolfgang Prause; Prause Wolfgang; Martin Aigner; Aigner Martin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-06       Impact factor: 5.270

2.  Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; H V Semlitsch; G Magni
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

3.  Inter- and intra-individual probability maps in EEG cartography by use of nonparametric Fisher tests.

Authors:  P Etévenon; A Bertaut; F Mitermite; F Eustache; J Lepaisant; B Lechevalier; E Zarifian
Journal:  Brain Topogr       Date:  1989 Fall-Winter       Impact factor: 3.020

4.  Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression.

Authors:  B Saletu; N Brandstätter; M Metka; M Stamenkovic; P Anderer; H V Semlitsch; G Heytmanek; J Huber; J Grünberger; L Linzmayer
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

5.  EEG-tomographic studies with LORETA on vigilance differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.

Authors:  M Saletu; P Anderer; G M Saletu-Zyhlarz; M Mandl; O Arnold; J Zeitlhofer; B Saletu
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 6.  Topographic mapping of EEG and evoked potentials in psychiatry: delusions, illusions, and realities.

Authors:  M W Torello
Journal:  Brain Topogr       Date:  1989       Impact factor: 3.020

7.  EEG brain mapping in evaluating the time-course of the central action of DUP 996--a new acetylcholine releasing drug.

Authors:  B Saletu; A Darragh; P Salmon; R Coen
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

8.  Facts and artifacts in brain electrical activity mapping.

Authors:  K L Coburn; M A Moreno
Journal:  Brain Topogr       Date:  1988       Impact factor: 3.020

9.  Brain mapping: a contribution to linear interpolation.

Authors:  D C Casaglia; G G Pantaleo
Journal:  Brain Topogr       Date:  1993       Impact factor: 3.020

10.  Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; L Linzmayer; H V Semlitsch; P Anderer; K Chwatal
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.